Experts question the emergency use authorization given to Bharat Biotech and AstraZeneca

New Delhi: After the latest decision to approve the vaccine by AstraZeneca and Oxford University as well as by Bharat Biotech for emergency use in India to immunise people against the COVID-19 virus; many experts have questioned the foundation of these approvals and reasons why other candidates such as Sputnik V and Pfizer were neglected in the process.

According to DCGI, Oxford-AstraZeneca Covid vaccine shows an average 70% effectiveness in preventing the virus. To which Dr. Debkishore Gupta, Consultant & Head- Clinical Microbiology & Infectious Diseases, Ruby General Hospital, Faculty, says, “This is the average efficacy between the normal group which received two full doses (62%) and half-dose and full dose (90%). India approved a full-dose regimen. Based on the full dose regimen for both shots that got approved, AZ had showed 62% efficacy based on their own paper submitted to the Lancet magazine; this is much lower than any other vaccine that has been approved in the world but yet to be approved by DCGI.”

Dr. Gupta goes on to add, “Trial is not yet complete in India. According to The Lancet- ‘In participants who received two standard doses, vaccine efficacy was 62.1% and in participants who received a low dose followed by a standard dose, efficacy was 90.0%. Overall vaccine efficacy across both groups was 70.4%.’ As India will possibly go by 2 full doses regimen, efficacy should have been quoted at 62.1%. The mention of the “overall” efficacy at 70% in this case is misleading. Moreover, AstraZeneca uses one and the same component for both inoculations, the Russian vaccine uses two different ones in two separate inoculations. Using the latter approach could prove more efficient in achieving a longer-lasting immune response.”

There has been ambiguity over AstraZeneca vaccine, ever since the data was published in the Lancet journal in the month of November last year proving that two full shots were 62.1% effective. AstraZeneca later announced plans to collaborate with Sputnik V whose efficacy showed to be 91.4% based on analysis of the data of the final control point of clinical trials. The partners will assess the immunogenicity and safety of the combined use of one of the components of the Sputnik V vaccine developed by the Gamaleya Center, and one of the components of the AZD1222 vaccine, developed by AstraZeneca and the University of Oxford. Such a combination should ultimately boost the efficacy the efficacy of AstraZeneca’s vaccine to over 90%.

Meanwhile, the makers of Sputnik V took to Twitter and shared, “Indian regulator recommends for approval full-dose regimen of AstraZeneca’s vaccine with efficacy of 62.1% based on phase 3 clinical data. Sputnik V is working on clinical trials with AZ to increase the efficacy of AZ vaccine to over 90%.”

Dr. Ashish Bharadwaj, Dean and Executive Director, Jindal School of Law adds: “Despite the logistical, financial and administrative requirements of this exercise and with the rampant spread of the virus, primacy must be placed on the candidate vaccine that has the higher proven efficacy and lowest probability for serious side-effects. AstraZeneca has reported in The Lancet an efficacy rate for its twin-shot vaccine that is lowest among the top contenders.”

“The approval of the Bharat Biotech and AstraZeneca vaccines on the primary basis will kickstart the vaccination campaign. However, in the longer run keeping in mind the demand of the largely populated country like India and India’s promises to other countries, approval of other vaccines such as Pfizer and Sputnik V which are in the queue, would also be very critical. Other players are equally important and in order to cater to the domestic and global demand, mass vaccination is the key,” says Dr. Gajendra Singh, Public Health Expert.

With these questions and recommendations by these experts, we hope that the Indian government takes an informed decision and give quick approvals or Emergency Use Authorization to other vaccine candidates as well.

By IANS

The English Post is on Telegram and WhatsApp, click to join for regular news updates